Rossari Biotech Limited (NSE:ROSSARI)
India
· Delayed Price · Currency is INR 467.00
-1.95 (-0.42%)
Apr 29, 2026, 3:30 PM IST
Rossari Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2021 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2021 - 2017 |
| Operating Revenue | 23,964 | 20,803 | 18,306 | 16,559 | 14,830 | Upgrade
|
| Other Revenue | 223.78 | - | - | - | - | Upgrade
|
| Revenue | 24,187 | 20,803 | 18,306 | 16,559 | 14,830 | Upgrade
|
| Revenue Growth (YoY) | 16.27% | 13.64% | 10.55% | 11.66% | 109.06% | Upgrade
|
| Cost of Revenue | 16,687 | 14,393 | 13,007 | 11,765 | 11,121 | Upgrade
|
| Gross Profit | 7,500 | 6,410 | 5,298 | 4,794 | 3,708 | Upgrade
|
| Selling, General & Admin | 1,547 | 1,401 | 1,098 | 1,039 | 726.02 | Upgrade
|
| Other Operating Expenses | 2,870 | 2,466 | 1,769 | 1,609 | 1,200 | Upgrade
|
| Operating Expenses | 5,209 | 4,538 | 3,471 | 3,277 | 2,416 | Upgrade
|
| Operating Income | 2,292 | 1,872 | 1,827 | 1,516 | 1,292 | Upgrade
|
| Interest Expense | -285.43 | -178.11 | -193.72 | -223.15 | -126.56 | Upgrade
|
| Interest & Investment Income | - | 8.57 | 22.39 | 25.21 | 49.77 | Upgrade
|
| Earnings From Equity Investments | 19.01 | 9.78 | 1.75 | 9.57 | 15.47 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 108.23 | 66.77 | 84.61 | 62.05 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 12.94 | 7.32 | 5.06 | 50.8 | Upgrade
|
| EBT Excluding Unusual Items | 2,025 | 1,834 | 1,732 | 1,418 | 1,344 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 18.98 | 25.68 | 7.07 | 12.52 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.69 | 18.78 | 2.83 | 6.38 | Upgrade
|
| Other Unusual Items | - | - | - | 14.67 | - | Upgrade
|
| Pretax Income | 2,025 | 1,852 | 1,776 | 1,442 | 1,363 | Upgrade
|
| Income Tax Expense | 533.02 | 488.07 | 469.26 | 369.62 | 385.8 | Upgrade
|
| Earnings From Continuing Operations | 1,492 | 1,364 | 1,307 | 1,073 | 976.95 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -0.21 | Upgrade
|
| Net Income | 1,492 | 1,364 | 1,307 | 1,073 | 976.74 | Upgrade
|
| Net Income to Common | 1,492 | 1,364 | 1,307 | 1,073 | 976.74 | Upgrade
|
| Net Income Growth | 9.41% | 4.35% | 21.85% | 9.81% | 21.76% | Upgrade
|
| Shares Outstanding (Basic) | 55 | 55 | 55 | 55 | 55 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 55 | Upgrade
|
| Shares Change (YoY) | 0.07% | 0.08% | -0.05% | 0.33% | 6.37% | Upgrade
|
| EPS (Basic) | 26.95 | 24.66 | 23.67 | 19.46 | 17.81 | Upgrade
|
| EPS (Diluted) | 26.93 | 24.63 | 23.62 | 19.38 | 17.70 | Upgrade
|
| EPS Growth | 9.34% | 4.28% | 21.88% | 9.49% | 14.41% | Upgrade
|
| Free Cash Flow | -1,996 | -210.69 | -880.28 | 1,187 | -88.67 | Upgrade
|
| Free Cash Flow Per Share | -36.02 | -3.81 | -15.91 | 21.44 | -1.61 | Upgrade
|
| Dividend Per Share | - | 0.500 | 0.500 | 0.500 | 0.500 | Upgrade
|
| Gross Margin | 31.01% | 30.81% | 28.94% | 28.95% | 25.01% | Upgrade
|
| Operating Margin | 9.47% | 9.00% | 9.98% | 9.16% | 8.71% | Upgrade
|
| Profit Margin | 6.17% | 6.56% | 7.14% | 6.48% | 6.59% | Upgrade
|
| Free Cash Flow Margin | -8.25% | -1.01% | -4.81% | 7.17% | -0.60% | Upgrade
|
| EBITDA | 3,083 | 2,486 | 2,418 | 2,138 | 1,768 | Upgrade
|
| EBITDA Margin | 12.75% | 11.95% | 13.21% | 12.91% | 11.92% | Upgrade
|
| D&A For EBITDA | 791.24 | 613.57 | 591.25 | 621.4 | 476 | Upgrade
|
| EBIT | 2,292 | 1,872 | 1,827 | 1,516 | 1,292 | Upgrade
|
| EBIT Margin | 9.47% | 9.00% | 9.98% | 9.16% | 8.71% | Upgrade
|
| Effective Tax Rate | 26.32% | 26.36% | 26.42% | 25.63% | 28.31% | Upgrade
|
| Revenue as Reported | 24,187 | 20,843 | 18,380 | 16,614 | 14,950 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.